LeMaitre Vascular, Inc. provides devices, implants, and services for the treatment of peripheral vascular disease. The company develops, manufactures, and markets disposable and implantable vascular devices for vascular surgeons, with products used in arteries and veins.
Recurring LMAT news includes quarterly financial results, guidance, dividend declarations, and management presentations at healthcare investor conferences. Company updates also discuss product categories such as Artegraft, grafts, valvulotomes, and carotid shunts, along with sales activity across the Americas, EMEA, and Asia Pacific.
LeMaitre (Nasdaq:LMAT) reported Q3 2021 sales of $38.4 million, a 5% increase year-over-year, with a gross margin of 64.8%, up 250 basis points. Operating income dropped 9% to $9.1 million, and net income fell 13% to $6.5 million. Earnings per diluted share were $0.30, down 19%. The company announced a quarterly dividend of $0.11 per share. Guidance for Q4 2021 expects sales between $39.0 million and $41.0 million, with a gross margin of 66.3%. CEO George LeMaitre noted challenges from the Delta variant affecting elective surgeries.
LeMaitre Vascular, Inc. (LMAT) will announce its Q3 2021 financial results on October 28, 2021, following the market's close. A conference call is scheduled for 5:00 PM ET that same day to discuss the results and company outlook. The call can be accessed by dialing 844-239-5284 (international: +1-512-961-6497) and is available via a webcast at www.lemaitre.com/investor. LeMaitre provides vascular devices for treating peripheral vascular disease, serving a global market of over 200 million individuals.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in four virtual investor conferences throughout September 2021. Key events include the Barrington Research 14th Annual Virtual Fall Investment Conference and Morgan Stanley's 19th Annual Global Healthcare Conference, both on September 9. Additionally, LeMaitre will participate in Lake Street's 5th Annual Best Ideas Growth Conference on September 14 and the 2021 Cantor Virtual Global Healthcare Conference on September 27, where David Roberts, President, will present at 8:00 AM ET.
LeMaitre specializes in devices and services for peripheral vascular disease, impacting over 200 million globally.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two investor conferences in August 2021. CFO JJ Pellegrino will present at the Canaccord Genuity 41st Annual Growth Conference on August 12 at 9:00 AM EDT and will also attend the Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 16. LeMaitre specializes in devices and services for treating peripheral vascular disease, which impacts over 200 million people globally.
LeMaitre (Nasdaq:LMAT) reported Q2 2021 results with sales of $40.7 million, a 64% increase year-over-year. Operating income rose by 128% to $11.1 million, yielding an operating margin of 27%. Net income jumped 137% to $8.3 million, with earnings per diluted share at $0.40, a 131% increase. Despite a gross margin decline to 65.8%, driven by product mix and manufacturing inefficiencies, the company completed a $54.5 million follow-on stock offering. Q3 2021 guidance suggests sales between $38.3 million and $40.3 million.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will announce its Q2 2021 financial results on July 29, 2021, after market close. A conference call is set for the same day at 5:00 PM ET to discuss the results and company outlook. The call can be accessed by dialing 844-239-5284 or through a webcast at the company’s investor relations page. LeMaitre specializes in devices for peripheral vascular disease, serving over 200 million worldwide.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) has priced a public offering of 1,000,000 shares at $54.50 each, expecting gross proceeds of approximately $54.5 million. Closing is anticipated around July 16, 2021. Underwriters have an option to buy 150,000 additional shares. Proceeds will be used to repay senior secured credit facility borrowings, for corporate purposes, and potential acquisitions. The offering follows SEC registration and is conducted via a prospectus. Jefferies and Stifel are the joint book-running managers for this offering.
LeMaitre Vascular (Nasdaq:LMAT) has begun an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of shares. The proceeds will be used to fully repay borrowings under its senior secured credit facility and for corporate purposes, including working capital and potential acquisitions. Jefferies LLC and Stifel are the joint book-running managers. The offering is subject to market conditions, and details will be available in the SEC filings.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced preliminary Q2 2021 results, reporting net sales of $40.7 million, a 64% increase compared to Q2 2020, with organic growth of 35%. Operating income reached approximately $10.9 million to $11.3 million, up 128%. The gross margin declined to 65.5%-66.1%, impacted by inventory write-downs and manufacturing inefficiencies. Geographic sales growth was strong across all regions, especially in the Americas (+83%). Cash and cash equivalents stood at $21.8 million, while debt decreased by $9 million to $23 million.
LeMaitre Vascular (Nasdaq:LMAT) announced that President David Roberts will present at the Goldman Sachs 42nd Annual Virtual Global Healthcare Conference on June 10, 2021, at 5:30 PM ET. The company specializes in devices, implants, and services for peripheral vascular disease, affecting over 200 million people globally. LeMaitre develops and markets vascular devices tailored to vascular surgeons.